The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
Proprietary consumer insights on attitudes, uses and behaviours
Deep dives into the most transformative compounds and companies
Key regulations, transformative trends and commercial opportunities
PSYCH Symposium is the industry's most influential virtual conference. Taking place on November 17-20, as part of Prohibition Partners LIVE, PSYCH Symposium will bring together distinguished industry thoughtleaders and rising entrepreneurs and operators to share insights and help develop this emerging frontier. The inaugural event will host stakeholders from the political, scientific, medical and business verticals of the global industry to promote the understanding, research and growth of psychedelics as a medicine.
Delegates will receive an in-depth analysis on the current regulatory landscape, clinical evidence, commercial opportunities and a presentationg on Prohibition Partners' proprietary consumer research. With limited information currently available on the nascent industry, the PSYCH Symposium marks a significant milestone for this emerging industry. Super early bird tickets end October 8th. Book your place now.
HIGHLIGHTS AND INSIGHTS
PSYCH: What are the next steps
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
We're pleased to announce that Dr David Luke, a Senior Lecturer in Psychology at Greenwich University & Director of Breaking Convention (@breakingcon), will be speaking during The Psych Symposium at @PPLIVE_.
Secure your place at our November event, here:
The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights & market intelligence from experts & industry leaders, helping to guide investors, operators & regulators through this transient phase. Download your free copy now.